{
    "paper_id": "0ece6547fc04c80f63d0a7e2ace7aa9b7443f192",
    "metadata": {
        "title": "",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Subject Index NOTES Cross-reference terms in italics are general cross-references, or refer to subentry terms within the main entry (the main entry is not repeated to save space). Readers are also advised to refer to the end of each article for additional cross-references -not all of these cross-references have been included in the index cross-references.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "The index is arranged in set-out style with a maximum of three levels of heading. Major discussion of a subject is indicated by bold page numbers. Page numbers suffixed by T and F refer to Tables and Figures respectively.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "This index is in letter-by -letter order, whereby hyphens and spaces within index headings are ignored in the alphabetization. Prefixes and terms in parentheses are excluded from the initial alphabetization.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "vs. indicates a comparison."
        },
        {
            "text": "To save space in the index, the following abbreviations have been used:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "vs. indicates a comparison."
        },
        {
            "text": "ALI -acute lung injury ARDS -acute respiratory distress syndrome BAL -bronchoalveolar lavage BPD -bronchopulmonary dysplasia CAP -community-acquired pneumonia CFTR -cystic fibrosis transporter regulation COP -cryptogenic organizing pneumonia COPD -chronic obstructive pulmonary disease CWP -coal workers' pneumoconiosis G-CSF -granulocyte colony-stimulating factor GERD -gastroesophageal reflux disease GM-CSF -granulocyte-macrophage colony-stimulating factor HUVS -hypocomplementemic urticarial vasculitis syndrome IL-interleukin IPF -idiopathic pulmonary fibrosis IPH -idiopathic pulmonary hemosiderosis MCP -monocyte chemoattractant protein M-CSF -macrophage colony-stimulating factor MIP -macrophage inflammatory protein MMP -matrix metalloproteinase NSCLC -non-small cell lung carcinoma PPAR -peroxisome proliferator-activated receptor SCLC -small-cell lung carcinoma SP -surfactant protein TGF -transforming growth factor TIMP -tissue inhibitor of metalloproteinases TNF -tumor necrosis factor VEGF -vascular endothelial growth factor Actin 1:564 binding proteins 1:565 myofibroblasts 3:67, 3:69 non-muscle cells 1:564 striated muscle 1:562 structure 1:563F, 1:564 see also Microfilaments a-Actin, airway smooth muscle ontongeny 4:98-99 Activated partial thromboplastin time (APTT), heparin therapy 3:580-581, 3:587-588 Activated protein C (APC) 1:484 as anticoagulant 1:125, 1:522, 1:522F mode of action 1:125, 1:126F biological functions 1:522, 1:523F antiapoptotic properties 1:125 as anticoagulant see Activated protein C (APC), as anticoagulant anti-inflammatory properties 1:125 cell survival 1:524 factor Va degradation 1:484, 1:492, 1:522 factor VIIa degradation 1:484 factor VIIIa degradation 1:522 fibrinolysis 1:522 inflammation inhibition 1:522 inflammatory cytokine blocking 1:522 p53 expression blocking 1:524 plasminogen activator inhibitor-1 inactivation 1:522 tissue remodeling 1:522 bronchial allergic inflammation 1:524 lipopolysaccharide (LPS) 2:85 platelet-derived growth factors effects 3:346-347 therapy with allergic bronchial inflammation 1:524-525 ARDS 1:524-525 PROWESS clinical trials 1:528 pulmonary fibrosis 1:502-503 Activating protein-1 see AP-1 (activating protein-1) transcription factor Active cycle breathing techniques (ACBT) 3:334 breathing control 3:334 hyperinflation 3:334 panic attacks 3:334 shortness of breath 3:334 forced expiratory technique (FET) 3:334, 3:335F bronchial chest clearance 3:335 equal pressure point 3:334-335 indications 3:334 lower thoracic-expansion exercises (LTEE) 3:334 atelectasis 3:334 precautions 3:334 sniff maneuver 3:334 Active site inhibited factor VII 1:124 Active sodium transport, alveolar fluid clearance 3:545 Activins 4:278-279; see also Transforming growth factor-b (TGF-b) Acute respiratory distress syndrome (ARDS) (continued) tissue factor 1:531-532, 1:532F urokinase-type plasminogen activator 2:207 definition 1:12 diagnosis 1:12, 1:12T; 3: 547T BAL see Acute respiratory distress syndrome (ARDS), BAL pulmonary function testing 1:13 radiology see Acute respiratory distress syndrome (ARDS), radiology differential diagnosis amiodarone-induced pulmonary disease vs., 2:44-46 idiopathic acute eosinophilic pneumonia vs., 4:223-224 disease severity 1:13 scoring systems 1:13 etiology 1:11, 1:11T adhesive atelectasis 1:215, 1:217-218 chemical inhalation injury 3:187, 3:209 esophageal sclerotherapy 3:554 miliary tuberculosis 3:454 predisposing conditions 1:11-12 pulmonary edema 3:546 sepsis 1:11-12 Air quality guidelines (continued) nitrogen trichloride (trichloramine) 2:104T ozone 2:104T Airspace consolidation, computed tomography 2:639, 2:640F Airspace enlargement cathepsin G 4:6-7 neutrophil elastase 4:6-7 proteinase-3 4:6-7 serine proteinases 4:6 urokinase-type plasminogen activator 4:6-7 Airway(s) bifurcation expiratory gas flow 2:62 inspiratory gas flow 2:61 cell nutrition 1:256 see also Immunoglobulin(s) (Igs) see also specific antibodies Antibody-dependent cytotoxicity, Mac-1 1:341 Anti-C1q antibodies 2:298, 2:300, 2:301 Anti-CD20 monoclonal antibodies 4:206 Anti-centromere antibodies 3:495-496 Anticholinergic bronchodilators 1:285-288 adverse events 1:287 asthma 1:174 acute 1:198, 1:287 available agents 1:286 chemistry 1:285, 1:285F clinical uses 1:286 pediatric airways disease 1:287 see also specific diseases/disorders COPD 1:285 acute 1:287 b-adrenergic agent combinations 1:287 b-adrenergic agents vs., 1:286-287 chronic 1:286 efficacy 1:286-287 mode of action 1:285 airway smooth muscle relaxants 1:286 muscarinic receptor interactions 1:285-286 side effects 1:287 bronchospasm 1:287-288 taste effects 1:287-288 stable asthma 1:287 b-adrenergic agents vs., 1:287 therapeutic margin 1:287-288 see also specific agents Anticholinesterases, myasthenia gravis management 3:129 Alpha-1-antichymotrypsin (ACT) 3:507-511 biological functions 3:507, 3:510, 3:510F",
            "cite_spans": [
                {
                    "start": 2933,
                    "end": 2937,
                    "text": "547T",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "vs. indicates a comparison."
        },
        {
            "text": "in Alzheimer's disease 3:508 chemotaxis 3:508 inflammation balance 3:510, 3:510F proteinase inhibition 3:508 genetics 3:508, 3:509F receptor 3:507-508 regulation 3:508 cytokines 3:508-509 in respiratory diseases 3:509 COPD 3:509-510 structure 3:507, 3:508F reactive center loop 3:507-508 ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "vs. indicates a comparison."
        },
        {
            "text": "CD18 association see p150 pregnancy 3:578 surgery 3:578 see also Pulmonary embolism Defense systems 2:1-7 conserved genes 2:3 physical barriers 2:2 soluble mediators 2:2 see also Immune responses Defensin(s) 2:7-10, 2:8T animal models 2:9 deficiency 2:9 biological functions 2:9, 2:9F bacterial membrane integrity 2:9 chemotaxis 2:9 mast cell degranulation 2:9 pathogen killing 2:7-8 genetics 2:8 polymorphisms 2:8 historical perspectives 2:7-8 infection defense 2:4 receptors 2:10 CCR6 2:10 regulation 2:8 cellular production 2:8-9 microbial products 2:8-9 Paneth cell trypsin 2:8 phagocytosis actions 2:8 in respiratory diseases 2:10 a 1 -antitrypsin deficiency 2:10 ARDS 2:10 COPD 2:10 cystic fibrosis 2:10 diffuse panbronchiolitis 2:10 mycobacterial infections 2:10 pneumonia 2:10 pulmonary fibrosis 2:10 sarcoidosis 2:10 structure 2:8 see also specific types a-Defensin 2:7-8, 2:8T genes 2:8 infection defense 2:2 structure 2:8 b-Defensin 2:8, 2:8T cellular production 2:8-9 IL-17 2:398 A 3 adenosine receptors 1:27-28 activated protein C 1:522 amorilide-sensitive epithelial sodium channels 2:473-474, 2:475 alpha-1-antichymotrypsin 3:510, 3:510F AP-1 transcription factor 4:247 bleomycin-induced pulmonary disease 3:560 bombesin 2:524 bradykinin 2:504, 2:505 bronchial circulation 1:258 C5a complement protein 1:548 CCL11 (eotaxin-1) 2:126 CCL24 (eotaxin-2) 2:126 CCL26 (eotaxin-3) 2:126 CD14 1:345-346 biological functions 2:397 chemokine production 2:397 CXC chemokine production 2:397-398 CXCL1 production 2:398 cyclooxygenase-2 production 2:398 cytokine production 2:397 b-defensin production 2:398 G-CSF production 2:398 GM-CSF production 2:398 granulocyte chemotaxis 2:398 IL-1b production 2:398 IL-1 receptor antagonist production 2:398 IL-4 synergy 2:398 IL-6 production 2:398 IL-8 production 2:398 IL-10 production 2:398 IL-11 production 2:398 IL-12 production 2:398 IL-13 synergy 2:398 immune response 2:398 inducible nitric oxide synthase 2:398 inflammatory mediators 2:398 innate immune response 2:398 interferon-g synergy 2:398 macrophage inflammatory protein-3 production 2:398 MMP production 2:398 neutrophil chemotaxis 2:397-398, 2:398 neutrophil differentiation 2:398 prostaglandin E 2 production 2:398 receptor-activator of NFkB ligand production 2:398 fever 3:2 receptors 3:2 polymorphisms 3:4 regulation 3:1 IL-1 3:1-2 TNF-a 3:1-2 in respiratory diseases 3:2 asthma 3:4 bleomycin-induced damage 3:2 collagen deposition 3:3 Cryptococcus neoformans infection 3:4 interstitial lung disease 3:3 invasive pulmonary aspergillosis 3:3-4 IPF 3:3 pneumonitis 3:3 structure 3:1 see also specific types Macrophage inflammatory protein-1a (MIP-1a: CCL3) biological functions 3:2, 3:2T as chemokine 3:2 fever 3:2 ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "vs. indicates a comparison."
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "exercise-induced IL-15 receptor",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "2",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "positive airway pressure 1:16-17 extracorporeal gas exchange 1:17 fractional inspired oxygen 1:16 hypercapnia 1:16 partial liquid ventilation 1:17 positive end expiratory pressure 1in respiratory diseases 1:21-22, 1:21 cystic fibrosis 1:21-22 signal transduction 4:12-13 structure 1:20, 1:20F see also ADAMTSs ADAM-17, TNF-a activation 3:24-25 ADAM-33, asthma 1:208, 1:214 ADAM33 gene, allergy 1:66 ADAMTSs 1:19-23 associated diseases 1:22 acquired thrombocytopenic purpura 1:22-23 Ehler-Danlos syndrome 1:22-23, 1:23 Marfan syndrome 1:22-23 Weill-Marchesani syndrome 1:22-23 biological functions 1:22 protein ectodomain shedding 1:20 receptors 1:23 syndecan-1 1:22-23 regulation 1:22 a2-macroglobulin 1:22 TIMP 3 1:22 transcription 1:22",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "2:431 COPD 1:433, 1:434F, 1:453; 2:87 cryoglobulinemia 1:585 CWP 3:192-193 cystic fibrosis 1:603 dermatomyositis 3:480-481 particles see Ultrafine particles upper respiratory tract infections 4:387 vascular remodeling 4:111 vasoactive intestinal peptide 2:519 see also specific cytokines Inflammatory bowel disease (IBD) 3:554 bronchiectasis 3:554 purulent bronchitis 3:554 Inflammatory myofibroblastic tumor (IMFT) 4:317",
            "latex": null,
            "type": "figure"
        },
        "TABREF4": {
            "text": "see also Surfactant protein A (SP-A); Surfactant protein D (SP-D) Collectin liver-1 (CL-1) 1:534 Collectin of 43kDa (CL-43) 1:534 infection defense 2:2-3 Collectin of 46kDa (CL-46) 1:534 Collectin placenta 1 1:534 Colony forming unit-erythroid (CFU-E), Costal pleura see Pleura Costochondritis, chest pain 4:193 Co-trimoxazole, Pneumocystis pneumonia 2:291 Cotton dust exposure, byssinosis 1:194 Cough 4:177-182, 4:29 CREB, PU.1 transcription factor regulation 4:276 c-Rel see Nuclear factor kappa B (NF-kB)",
            "latex": null,
            "type": "table"
        },
        "TABREF7": {
            "text": "TGF-a 1:113 TGF-b 1:113; 4:279-280 thrombospondin 1 2:179 thrombospondin 2 2:179, 2:180-181 TIMP-3 3:12, 3:13F, 3:14 vasoactive intestinal peptide 2:519-520 see also Deficient animal models; Transgenic models K\u00f6 lliker-Fuse nuclei 3:132-133, 3:133F, Lateral basal segment right lower lobe, postural drainage 3:338F Latex, allergic reactions 1:79 Lecofloxacin, CAP therapy 3:429 Limited sleep studies, sleep apnea 4:43 Linear accelerators, radiotherapy 3:610 Linear elasticity theory, lung stress distribution 4:125 Lingula, postural drainage 3:338F Linguoplasty, sleep apnea surgery 4:73 Linkage analysis 2:237-238, 2:239 genetic association analysis vs., 2:239, 2:239T identification 2:239 Lod score 2:239 model-based identification 2:239 Liquid phase, gas diffusion 2:16 Lisch nodules, neurofibromatosis 3:93 Lisofylline, ARDS management 1:19T Los Angeles smog 2:111, 2:112 Lou Gehrig's disease see Amyotrophic lateral sclerosis (ALS) Lovastatin, fibrosis management 2:218 Low birth weight, COPD 1:430 Low-density lipoprotein receptor-related 410F cancer see Lung cancer (bronchogenic carcinoma) see Non-small cell lung carcinoma (NSCLC) see Small cell lung carcinoma (SCLC) capillaries see Pulmonary capillaries cholinergic activity 1:286 482F, 4:483 development see Lung development edema see Pulmonary edema elasticity, cystatins 3:514 embolism see Pulmonary embolism expansion, first breath 1:252 fibrosis see Pulmonary fibrosis fluid homeosatsis see Fluid homeostasis function see Pulmonary function function tests see Pulmonary function testing hemosiderosis see Pulmonary hemosiderosis herniation, cleft sternum 4:165 histiocytosis X see Pulmonary histiocytosis X hyperplasia see Pulmonary hypoplasia hypertension see Pulmonary hypertension sounds see Lung sounds stress distribution see Stress distribution, lung thromboembolism see Pulmonary thromboembolism transplantation see Lung transplantation vascular disease see Pulmonary vascular disease vascular tone see Pulmonary vascular tone vasculature see Pulmonary vasculature veins see Pulmonary veins intra-acinar units 2:617 pulmonary artery 1:111 VEGF 2:617; 4:414-415, 4:415 Lung function see Pulmonary function Lung function testing see Pulmonary function testing Lung Health Study 1:461 Lung Injury Score (LIS), ARDS 1:13 disease-specific guidelines 4:173T rejection see Lung transplant rejection see also Heart/lung transplantation in respiratory tract 2:650 structure 2:649-650, 2:650, 2:651F transgenic overexpression 2:2 Lysyl oxidase, elastin regulation 2:163-164M M 1 muscarinic receptors see Acetylcholine receptors M 2 muscarinic receptors see Acetylcholine receptors M 3 muscarinic receptors see Acetylcholine receptors M 4 muscarinic receptors 1:3 M 5 muscarinic receptors 1:3 Mac-1 see Integrin a M b 2 (Mac-1: CD11b/ CD18) Macleod's (Sawyer-James) syndrome 1:261 Macroglossia, primary amyloidosis 2:421",
            "latex": null,
            "type": "table"
        },
        "TABREF8": {
            "text": "Minute volume, total ventilation 4:429 see also specific subunits temporal factors 4:248 therapeutic applications 4:268 see also Inhibitor protein kappa B (I-kB) Nuclear factor of activated T cells(NFAT)  4:246-247 Nuclear hormone receptors, zinc fingers 4:246 obstructive lung diseases 3:177 fruits and vegetables 3:177 reference daily intakes 3:173 in respiratory diseases airway hyperresponsiveness see Nutrition, airway hyperresponsiveness asthma 1:210; 3:178 BPD prevention/management 1:304 COPD 3:177 dyspnea management 4:188 obstructive lung diseases see Nutrition, obstructive lung diseases wheeze 3:178 sources 3:173 see also specific nutrients OA see Occupational asthma (OA) Oat-cell cancer see Small cell lung pulmonary mechanics 3:181 diffusing lung capacity 3:181-182 expiratory reserve volume 3:181-182 forced expiratory volume in one second (FEV 1 ) 3:181-182 functional lung capacity 3:181-182 inspiratory capacity 3:181-182 maximal voluntary ventilation 3:181-182 pulmonary function testing 3:181-182 total lung capacity 3:181-182 vital capacity 3:181-182 sleep-related conditions 3:183 road traffic accident association 4:50 upper airway resistance syndrome vs., 4:92 Occludin, tight junctions 1:33, 1:38-39 Occlusion techniques, infant pulmonary function testing 3:567T Occupational allergic rhinitis 1:81-82 Occupational asthma (OA) 1:187-195, 1:170; 3:187 allergic sensitization 3:187 agents 3:187 animal models 1:191 airway hyperresponsiveness 1:192 exposure threshold levels 1:192 IgE 1:191-192 IgG 1:191-192 Th2 cells 1:191-192 classification 1:187 clinical features 1:188, 1:189 airway responsiveness 1:188 bronchoconstriction 1:188 clinical history 1:189 inhalation challenge tests 1:190, 1:191F, 1:192F mild late reactions 1:190 peak expiratory flow 1:190 return-to-work studies 1:190, 1:193F serological investigations 1:190 spirometric monitoring 1:190-191 toxicity pathway 1:189 COPD vs., 1:188 definitions 1:187 epidemiology 1:188 189T airway hyperresponsiveness 1:188 hypersensitivity reactions 1:187-188, 1:189-190 impact on work market 1:193-194 management 1:193 compensation 1:194 exposure avoidance 1:193, 1:194 prevention 1:194 without latency see Asthma, irritantinduced see also Reactive airways dysfunction syndrome (RADS) Occupational diseases 3:186-191 acute inhalation injuries 3:187 toxic acute pneumonitis 3:187 toxic acute tracheobronchitis 3:187 asbestos-induced see Asbestos-induced lung diseases asthma see Occupational asthma (OA) BAL 1:279 berylliosis see Berylliosis see Chronic beryllium disease (CBD) chemical inhalation injury see Inhalation injury, chemical COPD see Chronic obstructive pulmonary disease (COPD) CWP see Coal workers' pneumoconiosis (CWP) definition 3:186-187 epidemiology 3:186 infections 3:189 interstitial lung disease 3:188 chronic beryllium disease 3:188 extrinsic allergic alveolitis see Hypersensitivity pneumonitis (HP) hard-metal lung disease 3:189 hypersensitivity pneumonitis see Hypersensitivity pneumonitis (HP) pneumoconioses 3:188; see also Asbestosis; Coal workers' pneumoconiosis (CWP); Silicosis IPF 2:446 lipopolysaccharide (LPS) exposure 2:82 lung cancer see Lung cancer (bronchogenic carcinoma) pleural disease see Pleural disease respiratory disease examination 4:27 Sentinel Event Notification System for Occupational Risks 3:186 silicosis see Silicosis SWORD 3:186 underreporting 3:186 Omalizumab, allergy management 1:70 Omega-3 polyunsaturated fatty acids 3:173, 3:174T airway hyperresponsiveness 3:179 asthma 3:178 COPD 3:177-178 inflammation, effects on 3:173 obstructive lung diseases 3:177 COX-2 expression 3:256 cytokine release 3:256 eotaxin expression 3:257 E-selectin expression 3:256 as growth factor 3:255 growth factor expression 3:255-256 prostaglandin E 2 expression 3:256 P-selectin expression 3:256 TIMP-1 expression 3:257 tissue damage limitation 3:254-255 TNF-a inhibition 3:256 Ondine's curse see Central sleep apnea (CSA) see Congenital central hypoventilation syndrome Open pleural biopsy 3:367 central pattern generator 3:146-147 receptors 2:525-526 Opisthorchis infections 4:219 Opsonins, collectins 1:537-538 Oscillating beds, ventilator-associated pneumonia prevention 4:470 Oseltamivir 1:131-132 contraindications 1:132-133 formulation 1:131-132 influenza treatment 1:131-132; 3:459 immunocompromised host 3:473 mechanism of action 1:132 respiratory virus infections 4:488 structure 1:130F OSER test, sleep disorders 4:79 OSI-774 see Erlotinib Osmium, acute chemical pneumonitis 3:214 Osmotic gradient reversal, fetal lung liquid clearance 1:248 Osteopetrotic mice (Op/Op), 1:544 long-term effects 2:102-103 pulmonary function 2:102 short-term effects 2:102, 2:102F formation 2:101, 2:101F free radical generation 2:92 inflammatory response 2:92-93 physicochemical properties 2:101T p22 phox , NADPH oxidase 3:80 p40 see Interleukin-9 (IL-9) p40 phox , NADPH oxidase 3:80 p47 phox , NADPH oxidase 3:80 p50 see Nuclear factor kappa B (NF-kB) p52 see Nuclear factor kappa B (NF-kB) p53 gene acetylation 2:41 asbestos-induced mesothelioma 3:224-225 blocking, activated protein C 1:524 DNA damage cell cycle checkpoint 1:352 lung carcinoma 1:354; 4:250, 4:328 p63 protein, basal cells 1:229-230, 1:232 p67 phox , NADPH oxidase 3:80 p100, nuclear factor kappa B 4:266F p105 see Nuclear factor kappa B (NF-kB) p120, adherent junctions 1:32 p150,95 1:338-339, 1:340T 443F negative pressure ventilation 4:452 obesity-hypoventilation syndrome 3:184 plasticity 4:445 respiration, control of 4:186 Paediatric aspiration syndromes 3:309-312 see also specific diseases/disorders PAF-specific acetylhydrolase 2:589 PAH see Pulmonary arterial hypertension Pancreas, cystic fibrosis 1:604 Pancreatic enzyme replacement, cystic fibrosis therapy 1:608 Pancreatic insufficiency, CFTR 1:613 Pancreatic sarcoidosis 4:201 Pancreatitis 3:554 Pancytopenia, chronic idiopathic myelofibrosis 3:491 Pandemics, influenza 3:456-457 Paneth cell trypsin, defensin regulation 2:8 Panic attacks, breathing control 3:334 SP-D 4:156, 4:156T Pathological scoring, COPD 1:452 Patient inhalation characteristics, inhaled drug delivery 1:59 Pattern recognition molecules see Collectin(s) see Pathogen-associated molecular patterns (PAMPs) Pattern recognition receptors (RRs) 4:237 PAVMs see Pulmonary arteriovenous malformations (PAVMs) Paxillin 1:45 PCO 2 measurement 1:146 transcutaneous 1:147, 1:147F PCO 2 electrode 1:146, 1:146F historical perspective 1:146 Peak cough flow, upper motor neuron diseases 3:122, 3:123F PECAM-1 see Platelet-endothelial adhesion molecule-1 (PECAM-1) PEComas 4:316-317 Pectoral muscles 3:634F, 3:635-636 Perennial allergic rhinitis 1:81-82 Peribronchial cuff formation, interstitial compliance vs. airway/vascular resistance 4:128-129 Peribronchial lymphatic plexus 4:367 Peribronchial pressure, perivascular pressure vs., 4:129 Peribronchovascular connective tissue 2:643-644 Pericardial cysts see Mediastinal masses Pericardial friction rub, postcardiac injury syndrome 3:380-381 Pericardial infections, cleft sternum Peripheral gas exchange 3:315-323 oxygen transport pathway see Oxygen transport/utilization Peripheral lesions, cancer diagnosis, bronchoscopy 1:307 Peripheral nerve disorders 3:113-118 animal models 3:117 classification 3:113, 3:115T connexins 1:560 drug-induced 3:115T systemic diseases 3:114T see also specific diseases/disorders Peripheral noncartilaginous airways, airway smooth muscle 4:97 Peritonsilar abscess, croup vs., 1:583 Perivascular cuff formation, interstitial compliance vs. airway/vascular resistance 4:128-129 Perivascular pressure interstitial fluid cuff growth 4:129 peribronchial pressure vs., 4:129 Perivascular surface, interstitial fluid pressures vs., 4:128 Persistent allergic rhinitis 1:82 Persistent atopic wheeze, asthma 1:208 Persistent fetal circulation (PFC), neonatal breathing 1:238 PEST domain, PU.1 transcription factor structure 4:274-275 Petechiae, sudden infant death syndrome 4:132-133 PGE 2 brake hypothesis see Aspirin-Laryngitis; Tonsillitis Phasic smooth muscle 1:563 pH electrode 1:145, 1:145F historical perspective 1:145-146 Phenindione 1:117T structure 1:119F COPD 3:335-336 head-down position 3:336 high side lying 3:339F lateral basal segment right lower lobe 3:338F left lateral basal segment, lower dyspnea 3:336 forward kneeling 3:337, 3:341F forward lean sitting 3:337, 3:340F forward lean standing 3:337, 3:340F relaxed sitting 3:337, 3:339F relaxed standing 3:337, 3:340F upright sitting 3:337 Pickwickian syndrome see Obesity-Pigeon breeder's lung 3:189 'Pink puffers,' COPD 4:21 Pinocytosis 4:479F, 4:481 pleural transport 3:400 Pioglitazone, PPAR activation 3:329 Piperacillin/tazobactem, nosocomial pneumonia management 3:445-446 Pirfenidone, IPF management 2:448 Placenta, vascular resistance 3:87 Plakoglobin 1:40 Plakophilins 1:40 Plaque proteins, tight junctions 1:39 Plaques, tracheobronchial amyloidosis 2:425, 2:425F PLAS1 (protein inhibitor of activated STAT1), cystic fibrosis 4:250 Plasma, proteome/proteomics 3:530 Plasma cells BAL 1:280, 1:280F eosinophilic pneumonia 1:280 diffuse panbronchiolitis 3:297-298 immunoglobulin secretion 2:317-318 pleural fluid analysis 3:366 see also B cell(s) Plasmacytoid dendritic cells 2:12, 2:564-565 Plasmacytomata 4:340, 4:341F Plasma extravasation, capsaicin 1:317 Plasma kallikrein see Kallikreins Plsntinol s see Cisplatin Pluripoetin-a see Granulocyte-macrophage colony-stimulating factor (GM-CSF) PM 2.5 , ultrafine particles 2:106 PM 10 , ultrafine particles 2:106 pMDIs see Pressured metered dose inhalers (pMDIs) PMF see Progressive massive fibrosis Pneumocystis carinii infection see Pneumocystis jiroveci infection Pneumocystis jiroveci infection BAL 1:281F culture 1:283-284 eosinophils 1:283 plasma cells 1:280 computed tomography 2:640-641 CXCL1 (GROa) 1:408-409 MCP-1 1:373 prophylaxis, post-lung transplantation 4:174 radiology 3:426 SP-A effects 4:145 urokinase-type plasminogen activator 1:516 see also Pneumocystis pneumonia (PCP) Pneumocystis pneumonia (PCP) 3:469 HIV infection see HIV infection Pneumonectomy, complications 4:295; see also Postpneumonectomy syndrome pulmonary arterial hypertension differential diagnosis, relapsing Secondary granules, neutrophils 2:548 brain metastases 4:368-369 Talin biological functions 1:44 integrin regulation 1:43, 1:50 see also Integrin(s) structure 1:43-44 Tandem repeat domain, mucins 3:57, 3:57F Tanomastat, clinical trials 3:17 TARC see CCL17 (TARC) Tarceva s see Erlotinib TATA-binding protein, transcription 2:231-232 TATA box sequence, transcription 2:231-232 TATA-less promoters, gene regulation 2:232 Tau protein, microtubules 1:618 Taxol s see Paclitaxel Taxotere s see Docetaxel TBP-associated factors (TAFs)Toll-like receptors 2:557-558 biological functions 2:559 cell-mediated immune response 2:558-559 humoral immune response 2:558-559 peripheral tolerance 2:13-14 self-tolerance induction 2:559 bronchus-associated lymphoid tissue Wegener's granulomatosis 2:562 in therapy 2:562 trafficking, RANTES 1:378 see also CD4+ T cells; CD8+ T cells T-cell alveolitis, IL-15 2:388-390 T-cell lymphoma 4:343 in respiratory diseases 1:388, 1:388F structure 1:385, 1:386F homology 1:385, 1:386T Telangiectasias 3:556 in respiratory diseases, asthma 3:178 Vitamin B 12 deficiency, anemia 2:144-145 Vitamin C (ascorbic acid) 3:172-173, 3:174T, 3:267, 3:283-284 dietary intake assessment 3:176 Vitamin D 3 receptor, sarcoidosis 4:250 Vitamin E 3:172-173, 3:174T, 3:267, 3:283-284 dietary intake assessment 3:176 Voltage-gated calcium channels see Calcium channels Voltage-gated potassium channels see Potassium channels Volutrauma, BPD 1:301 Vomiting see Nausea/vomiting von Recklinghausen's disease see Neurofibromatosis, type 1 (von Recklinghausen's disease) von Willbrand factor, endothelial cells 2:70 Voriconazole, aspergillosis management 3:437 VP-16 see Etoposide VPAC1, vasoactive intestinal peptide receptors 2:518-519 VPAC2, vasoactive intestinal peptide receptors 2:518-519 V/Q regulation, myofibroblasts 3:69 V/Q scan, pulmonary veno-occlusive disease 4:407 V segments, immunoglobulins 2:316-317",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "interstitial lung disease 3:3 invasive pulmonary aspergillosis 3:3-4 IPF 1:363; 3:3 pneumonitis 3:3 respiratory syncytial virus infection 1:364-365, 1:365 sarcoidosis 2:571 tuberculosis 1:364 structure 3:1 Macrophage inflammatory protein-1b (MIP-1b: CCL4) biological functions 3:2T as chemokine 3:2 fever 3:2 nomenclature 1:357T pneumonitis 3:3 receptors 3:2 regulation IL-4 3:1-2 IL-10 3:1-2 in respiratory diseases graft-versus-host disease 1:364 IPF 1:363 respiratory syncytial virus infection 1:364-365, 1:365 tuberculosis 1:364 structure 3:1 Macrophage inflammatory protein-1d (MIP-1d: CCL15) biological functions 3:2, 3:2T nomenclature 1:357T receptors 3:2 regulation 3:1-2 Macrophage inflammatory protein-1g (MIP-1g: CCL9/10) biological functions 3:2, 3:2T cell expression 3:1-2 nomenclature 1:357T receptors 3:2 regulation 3:1-2 structure 3:1 Macrophage inflammatory protein-2 (MIP-2) see Monocyte chemoattractant protein-1 (MCP-1: CCL2) Macrophage inflammatory protein-2a (MIP-2a) see CXCL2 (GROb) Macrophage inflammatory protein-2b (MIP-2b) see CXCL3 (GROg) Macrophage inflammatory protein-3a (MIP-3a: CCL20) biological functions 3:2, 3:2T nomenclature 1:357T receptors 3:2 regulation IL-10 3:1-2 IL-17 2:398 respiratory syncytial virus infection 1:364-365 structure 3:1 Macrophage inflammatory protein-3b (MIP-3b: CCL19) biological functions 3:2, 3:2T nomenclature 1:357T receptors 3:2 regulation 3:1-2 structure 3:1 Macrophage inflammatory protein-4 (MIP-4: CCL18) biological functions 3:2, 3:2T nomenclature 1:357T regulation 3:1-2 structure 3:1 Macrophage migration inhibitory factor (MIF) 3:5-9 biological functions 3:7 cell growth effects 3:7-8 chemokine expression 3:7 cyclin D1 expression 3:7 cytokine expression 3:7 DNA synthesis 3:7 fibroblasts 3:7 glucocorticoids 3:7 MAP kinase activation 3:7 phospholipase A 2 3:7 distribution 3:6T inflammatory cells 3:5 pituitary 3:5 historical perspective 3:5 knockout mice 3:5 Mif gene 3:5-6 polymorphisms 3:7 receptors 3:8 regulation 3:6 lipopolysaccharide 3:5, 3:6 signaling pathways 3:7 in respiratory diseases 3:7T, 3:8 ALI 3:8 allergies 3:8 animal models 3:8 ARDS 3:8 lung carcinoma 3:9 lung remodeling 3:8-9 neutrophilia 3:8 structure 3:5, 3:6F Macropinocytosis, dendritic cells 2:12 Maculopapular rash, ehrlichiosis 3:414 animal models 2:509 knockout 2:512-513 biological functions airway hypersensitivity 2:509 arterial chemoreceptors 1:420-421 breathing control see Substance P, breathing control bronchoconstriction 2:513 cell growth 2:514 cough 2:513 eosinophil chemotaxis 2:514 inflammation 2:513 mast cell degranulation 2:514 phagocytosis 2:514 secretions 2:513 breathing control 2:506-507, 2:507F afferent neuron signal integration 2:507 animal models 2:508 carotid body sensitivity 2:508 compensatory hyperventilation 2:508 cough response 2:508 hypoxic ventilatory response 2:508 'inspiratory off-switch,' 2:507 pre-B\u00f6 tzinger complex 2:507 respiratory rhythm control 2:507 degradation 2:512 distribution 2:510-512, 2:512T, 2:516F capsaicin reactions 2:512 gene 2:510 metabolism 2:509 angiotensin-converting enzyme 2:509 neutral endopeptidase 2:509 production 2:511F airway smooth muscle 3:141- apoptosis 3:11 cell adhesion 3:11 cell migration 3:11 growth factors 3:11 definition 3:10 in lung development 3:12 alveologenesis 3:12 bronchiole branching morphogenesis 3:12, 3:13F cannicular stage 3:12 lung bud formation 3:12 production eosinophils 2:544 fibroblasts 2:215-216 TGF-b 4:281 regulation 3:10-11 cytokines 3:10-11 expression 3:10-11 in respiratory diseases 3:14 ALI 3:16 COPD 1:454 emphysema 3:14, 3:15F lung carcinoma 3:16 lymphangioleiomyomatosis lesions 2:449-450 pulmonary fibrosis 3:16, 3:562 structure 3:10, 3:10F, 3:11T see also specific types Tissue inhibitor of metalloproteinase-1 (TIMP-1) 3:10 biological functions 3:11T bleomycin-induced lung injury 3:16 MMP interactions 3:10 production, oncostatin-M 3:257 structure 3:10, 3:10F, 3:11T Tissue inhibitor of metalloproteinase-2 (TIMP-2) 3:10 biological functions 3:11T MMP-2 activation 3:11-12 bleomycin-induced lung injury 3:16 MMP interactions 3:10 structure 3:10, 3:11T Tissue inhibitor of metalloproteinase-3 (TIMP-3) 3:10 biological functions 3:11T ADAM inhibition 3: 2:517-521 activation, mast cell tryptase 2:537 biological functions 2:518, 2:518T, 2:519, 2:519F antiapoptotic effects 2:519 bronchi 2:518 CXCL10 (IP-10) regulation 1:403-404 immune system 2:518, 2:519 inflammation 2:519 mast cell tryptase effects 1:465 pulmonary vasodilation 2:518, 2:519 smooth muscle contraction 2:518 smooth muscle relaxation 2:519 tracheobronchial secretions 2:518 vascular remodeling 4:110-111 distribution 2:517 acetylcholine colocalization 2:518 immunofluorescence 2:517-518 in lungs 2:518 radioimmunoassay 2:517-518 knockout animal models 2:519-520 receptors 2:518 PAC1 2:518-519 VPAC1 2:518-519 VPAC2 2:518-519 in respiratory diseases 2:519, 2:520F bronchial asthma 2:519 cystic fibrosis 2:520 primary pulmonary hypertension 2:520 pulmonary arterial hypertension 4:109 signal transduction 2:519 nitric oxide release 2:519 sources, airway smooth muscle 3:141 structure 2:517, 2:517F therapeutic applications 2:520, 2:521T ALI 2:520 ARDS 2:520 bronchial asthma 2:520 lung carcinoma 2:521 pulmonary arterial hypertension management 4:109-110 pulmonary hypertension 2:521 Vasoconstriction angiotensin II 3:541-542 endothelin- ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "annex"
        }
    ]
}